Neuraxpharm and mjn-neuro launch EPISERAS, an AI-powered epilepsy wearable

Neuraxpharm and mjn-neuro have launched EPISERAS, an AI-powered wearable device intended for seizure monitoring, marking the two companies' entry into the digital neurology market.

The announcement names the device and the partnership; the companies position EPISERAS as a wearable that applies artificial intelligence to detect and record seizure-related physiological signals. The launch pairs Neuraxpharm, a European pharmaceutical company focused on central nervous system disorders, with mjn-neuro, a developer of neurotechnology wearables.

What do we know about the device?

The launch confirms three concrete points:

• EPISERAS is a wearable, meaning ambulatory, body-worn monitoring rather than inpatient video-EEG.
• The device uses AI-based signal analysis.
• It targets people with epilepsy.

The announcement does not specify the underlying sensing modality — whether EPISERAS captures scalp EEG channels, electrodermal activity, accelerometry, electromyography or a multimodal combination. It also does not state whether the device holds regulatory clearance, such as FDA authorization or CE marking under the EU Medical Device Regulation, or whether clinical validation studies are complete or ongoing. Readers should treat detailed performance claims as pending until the companies publish validation data or regulatory documentation.

Why ambulatory seizure detection matters for clinical practice

For epilepsy centers, the clinical need is well defined. Scalp video-EEG monitoring remains the diagnostic reference standard, but it confines patients to an epilepsy monitoring unit for days. Many seizures — particularly nocturnal events and subtle focal seizures — go unreported by patients, whose self-reported diaries substantially underestimate seizure frequency. That measurement gap directly affects treatment decisions: antiseizure medication titration, driving eligibility and surgical candidacy all rest on seizure counts.

Wearable detectors aim to close that gap by providing continuous, long-duration monitoring in the patient's home environment. If EPISERAS validates with acceptable sensitivity and false-alarm rates in prospective cohorts, it could give treating neurologists objective seizure-frequency data between clinic visits.

AI analysis and what clinics should watch for

The "AI-powered" designation means the device applies machine-learning algorithms to biosignals to classify seizure events. For clinical neurophysiology teams evaluating whether to adopt such a tool, the key questions will be:

• What signals feed the algorithm, and with what montage or sensor configuration?
• What sensitivity and false-positive rate did validation studies achieve, and in which patient populations?
• Is the device cleared as a medical device in the relevant jurisdiction, or is it investigational?

None of these specifics appear in the launch announcement, so they will define the evidence clinicians should demand before integrating EPISERAS data into clinical decision-making.

A neurotech-pharma pairing

The collaboration structure itself is notable. Neuraxpharm brings a CNS-focused commercial footprint across European markets; mjn-neuro brings wearable hardware and algorithm development. Device-plus-pharma partnerships of this type often aim to pair monitoring data with medication management, although the companies have not announced any integrated digital-therapeutic program beyond the device launch itself.

Whether EPISERAS matures into a validated clinical tool will depend on peer-reviewed validation studies and regulatory status — the announcement opens that path, and the epilepsy monitoring community will be watching for the first sensitivity and specificity data.